Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
As a result of this acquisition Symphogen becomes Servier’s center of excellence for antibodies, strengthening the Group’s pipeline in various therapeutic areas, including oncology.
Lead Product(s): Sym021
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Servier
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition June 04, 2020
Details:
Servier will gain full ownership of Symphogen’s proprietary pipeline of oncology and immuno-oncology programs and Symphogen’s antibody discovery and development platform.
Lead Product(s): Sym021
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Servier Canada
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition April 03, 2020